Prialt

Prialt is an intravenous medication used to treat severe chronic pain not controlled by other methods. It is a synthetic analogue of the natural peptide delta opioid agonist, advisant, and is marketed under the brand name Prialt by Elan Pharmaceuticals.

Prialt was FDA-approved for use in the United States in 2002. It works by selectively activating delta opioid receptors in the brain and spinal cord, which helps to reduce the transmission of pain signals. Unlike other opioid medications, Prialt is designed to avoid activating mu opioid receptors, which are responsible for producing analgesia and euphoria. This targeted action allows Prialt to provide effective pain relief while minimizing the risk of abuse and dependency.

Prialt is administered via continuous intrathecal infusion, which involves delivering the medication directly into the spinal canal. This method allows for precise delivery of the medication and minimizes side effects. Prialt has been studied in a variety of clinical trials for treating various types of chronic pain, including intractable non-cancer pain and cancer pain.

Common side effects of Prialt include drowsiness, nausea, and vomiting. Other potential side effects include changes in blood pressure, dizziness, and headaches. Prialt is contraindicated in patients with a history of substance abuse or addiction. Medical professionals closely monitor patients taking Prialt due to the risk of respiratory depression and other serious adverse reactions.

Prialt is not without controversy, as some medical practitioners have raised concerns about its safety and efficacy in clinical use. However, the FDA and other regulatory agencies have approved Prialt for use under strict guidelines and dosing requirements.